Update on Invasive Candidiasis

Advances in Pharmacology

Volumn 37, Issue C, 1996, Pages 349-400

  Rodriguez, Libsen J ^a   Rex, John H ^a   Anaissie, Elias J ^b  

^a Infectious Diseases Center for the Study   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000903202     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60955-2     Document Type: Article

References (416)

1. Abadie-Kemmerly S., Pankey G.A., and Dalvisio J.R. Failure of ketoconazole treatment of Blustomyces dermutitidis due to interaction of isoniazid and rifampin. Ann. Intern. Med. 109 (1988) 844-845
2. Abbott M., Hughes D.L., Patel R., and Kinghorn G.R. Angio-oedema after fluconazole. Lancet 338 (1991) 633
3. Aguado J.M., Hidalgo M., and Ridriguez-Tudela J.L. Successful treatment of Candida peritonitis with fluconazole. J. Antimicrob. Chemother. 34 (1994) 847
4. Akler M.E., Vellend H., McNeely D.M., Walmsley S.L., and Gold W.L. Use of fluconazole in the treatment of candidal endophthalmitis. Clin. Infect. Dis. 20 (1995) 657-664
5. Anaissie E.J. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review. Clin. Infect. Dis. 14 Suppl. l (1992) S43-S53
6. Anaissie E., Bodey G.P., Kantarjian H., David C., Barnett K., Bow E., Defelice R., Downs N., File T., Karam G., Potts D., Shelton M., and Sugar A. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am. J. Med. 91 (1991) 142-150
7. Anaissie E., Paetznick V., Proffitt R., Adler M.J., and Bodey G.P. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 665-668
8. Anaissie E.J., Hachem R., Karyotakis A., Gokaslan A., Dignani C., Stephens L.C., and Tin-U C.K. Comparative efficacies of amphoterin B, triazoles and combination of both as experimental therapy for murine trichosporinosi. Antimicrob. Agents Chemother. 38 (1995) 2541-2544
9. Anaissie E.J., Kontonyiannis D.P., Huls C., Vartivarian S.E., Karl C., Prince R.A., Bosso J., and Bodey G.P. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J. Infect. Dis. 172 (1995) 599-602
10. Anaissie, E.J., White, M., Uzun, O., Singer, C., Bodey, G.P., D.M., Azarnia, N., and Lopez-Berenstein, G. (1995c), Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: A prospective, randomized, multicenter trial. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. LM21.
11. Anaissie E.J., Vartivarian S.E., Abi-Said D., Uzum O., Pinczowski H., Kontoyiannis D., Khoury P., Pappadakis A., Gardner A., Raad I., Gilbreath J., and Bodey G.P. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study. Am. J. Med. (1996) In press
12. Anderson P.L., and Stenderup A. Candida aibicans antibodies in candidiasis. Scand. J. Infect. Dis. 6 (1974) 69-73
13. Anonymous. Reports of dangerous cardiac arrhythmias prompt new contraindications for the drug hismanal. FDA Med. Bull. 23 (1993) 2
14. Anonymous. Diflucan (fluconazole tablets) (1994), Roerig Division of Pfizer, Inc., New York
15. Anonymous. Prograf (tacrolimus capsules) Product information (1994), Fujisawa, USA, Deer-field, IL.
16. Anonymous. Neutrexin (trimetrexate glucoronate for injection). Product information (1995), US Bioscience, Inc., West Conshohocken, PA.
17. Anonymous. Nizoral (ketoconazole tablets) (1995), Janssen Pharmaceutica, Titusville, NJ.
18. Anonymous. Sporanox (itraconazole capsules). Product information (1995), Janssen Pharmaceutica, Titusville, NJ.
19. Arning M., Dressen B., Aul C., and Schneider W. Influence of infusion time on the acute toxicity of amphotericin B: Results of a randomized double-blind study. Rec. Results Cancer Res. 121 (1991) 347-352
20. Ascher D.P., Shoupe B.A., Robb M., Maybee D.A., and Fischer G.W. Comparison of standard and quantitative blood cultures in the evaluation of children with suspected central venous line sepsis. Diagn. Microbiol. Infect. Dis. 15 (1992) 499-503
21. Atkinson A.J., and Bennett J.E. Amphotericin B pharmacokinetics in humans. Antimicrob. Agents Chemother. 13 (1978) 271-276
22. Auger P., Dumas C., and Joly J. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob. Agents Chemother. 22 (1982) 482-487
23. Ayub M., and Levell M.J. Inhibition of testicular 17-alpha-hydroxylase and 17,20-lyase but not 3 beta-hydroxysteroid dehydrogenase-isomerase or 17-beta-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs. J. Steroid Biochem. 28 (1987) 521-531
24. Baciewicz A.M., and Baciewicz F.A. Ketoconazole and fluconazole drug interactions. Arch. Intern. Med. 153 (1993) 1970-1976
25. Bailey J.W., Sada E., Brass C., and Bennett J.E. Diagnosis of systemic candidiasis by latex agglutination for serum antigen. J. Clin. Microbiol. 21 (1985) 749-752
26. Baine W.B., Koenig M.G., and Goodman J.S. Clearance of Candida albicans from the bloodstream of rabbits. Infect. Immun. 10 (1974) 73-78
27. Baley J.E., Annable W.L., and Kllegman R.M. Candida endophthalmitis in the premature infant. J. Pediatr. 98 (1981) 458-461
28. Banerjee S.N., Emori T.G., Culver D.H., Gaynes R.P., Jarvis W.R., Horan T., Edwards J.R., Tolson J., Henderson T., and Marone W.J. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am. J. Med. 91 Suppl. 3B (1991) 86s-89s The National Nosocomial Infections Surveillance System
29. Barton C.H., Pahl M., Vaziri N.D., and Cesario T. Renal magnesium wasting associated with amphotericin B therapy. Am. J. Med. 77 (1984) 471-474
30. Bennett J.E. Flucytosine. Ann. Intern. Med. 86 (1977) 319-322
31. Bennett J.E., Dismukes W.E., Duma R.J., Medoff G., Sande M.A., Gallis H., Leonard J., Fields B.T., Bradshaw M., Haywood H., McGee Z.A., Cate T.R., Cobbs C.G., Warner J.F., and Alling D.W. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N. Engl. J. Med. 301 (1979) 126-131
32. Berenguer J., Buck M., Witebsky F., Stock F., Pizzo P.A., and Walsh T.J. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn. Microbiol. Infect. Dis. 17 (1993) 103-109
33. Berkowitz I.D., Robboy S.J., Karchmer A.W., and Kunz L.J. Torulopsis glubrutu fungemia-A clinical pathological study. Medicine 56 (1979) 430-440
34. Bernard E., Christiansen K.J., Tsang S.F., Kiehn T.E., and Armstrong D. Rate of arabinitol production of pathogenic yeast species. J. Clin. Microbiol. 14 (1981) 189-194
35. Bernhardt H.E., Orlando J.C., Benfield J.R., Hirose F.M., and Foos R.Y. Disseminated candidiasis in surgical patients. Surg. Gynecol. Obstet. 134 (1972) 819-825
36. Bille J., Stockman G., Roberts D., Hortmeier C.D., and Ilstrup D.M. Evaluation of a lysis-centrifugation system for recovery of yeasts and filamentous fungi from blood. J. Clin. Microbiol. 18 (1983) 469-471
37. Bindschadler D.D., Bennet J.E., and Abernathy R.S. A pharmacologic guide to the clinical use of amphotericin B. Br. J. Infect. Dis. 120 (1969) 427-436
38. Blinkhorn R.J., Adelstein D., and Spagnuolo P.J. Emergence of a new opportunistic pathogen, Candida Iusitaniae. J. Clin. Microbiol. 27 (1989) 236-240
39. Block E.R., and Bennett J.E. Pharmacological studies with 5-fluorocytosine. Antimi-crob. Agents Chemother. 1 (1972) 476-482
40. Block E.T., Bennet J.E., Livoti L.G., Klein Jr. W.J., MacGregor R.R., and Henderson L. Flucytosine and amphotericin B: Hemodialysis efffects on the plasma concentration and clearance. Ann. Intern. Med. 80 (1974) 613-617
41. Blum R.A., D'Andrea D.T., Florentino B.M., Wilton J.H., Hilligoss D.M., Gardner M.J., Henry E.B., Goldstein H., and Schentag J.J. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann. Intern. Med. 114 (1991) 755-757
42. Blum R.A., Wilton J.H., Hilligoss D.M., Gardner M.J., Henry E.B., Harrison N.J., and Schentag J.J. Effect of fluconazole on the disposition of phenytoin. Clin. Pharmacol. Ther. 49 (1991) 420-425
43. Bode S., Pedersen-Bjergaard L., and Hjelt K. Candida albicans septicemia in a premature infant successfully treated with oral fluconazole. Scand. I. Infect. Dis. 24 (1991) 673-675
44. Bodey G.P. Fungal infections complicating acute 1eukemia. J. Chron. Dis. 19 (1966) 667-687
45. Bodey G.P., and Luna M. Skin lesions associated with disseminated candidiasis. JAMA 229 (1974) 1466-1468
46. Bodey G.P., Anaissie E.J., and Edwards J.E. Definitions of Candida infections. In: Bodey G.P. (Ed). "Candidiasis: Pathogenesis, Diagnosis, and Treatment" (1993), Raven Press, New York 407-408
47. Bodey G.P., Anaissie E.J., Eking L.S., Estey E., O'Brien S., and Kantarkian H. Antifungal prophylaxis during remission induction therapy for acute leukemia. Fluconazole versus intravenous amphotericin B. Cancer 73 (1994) 2099-2106
48. Body B.A., Pfaller M.A., Durrer J., Koonts F., and Groschel D.H.M. Comparison of the lysis-centrifugation and radiometric systems for recovery of yeast. J. Clin. Microbiol. 7 (1988) 417-420
49. Boelaert J., Schugers M., Matthys E., Daneels R., Van Peeer A., De Beule K., Woestenborghs R., and Heykants J. Itraconazole pharmacokinetics in patients with renal dysfunction. Antirnicrob. Agents Chemother. 32 (1988) 1595-1597
50. Bonay M., Jonville-Bera A.P., Diot P., Lemarie E., Lavandier M., and Autret E. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Safety 9 (1993) 309-311
51. Boogaerts M.A., Verhoef G.E., Zachee P., Demuynck K., Verbist L., and De Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels. Mycosis 32 (1989) 103
52. Borelli D., Brean J.L., Fuentes J., Legendre R., Leiderman E., Levine E., Restrepo-M A., and Stevens D.A. Ketoconazole and oral antifungal: Laboratory and clinical assessment of imidazole drugs. Postgrud. Med. J. 55 (1979) 657-661
53. Bougnoux M.E., Hill C., Moissente D., de Chauvin M.F., Bonnay M., Vicens-Sprauel I., Pietri F., McNeil M., Kaufman L., Dupouy-Camet J., Bohuon C., and Andremonti A. Comparison of antibody, antigen, and metabolite assays for hospitalized patients with disseminated or peripheral candidiasis. J. Clin. Microbiol. 28 (1990) 905-909
54. Bougnoux M.W., Gueho E., and Potocka A.-C. Resolutive Candida utilis fungemia in a nonneutropenic patient. J. Clin. Microbiol. 31 (1993) 1644-1645
55. Bowden R.A., and Cays M. Phase I safety study of amphotericin B colloidal dispersion (ABCD, Amphocil) for the treatment of invasive fungal infection after marrow transplant. Blood 82 (1993) 425a (abstract 1685)
56. Brammer K.W., and Coates P.E. Pharmacokinetics of fluconazole in pediatric patients. Eur. J. Clin. Microbiol. Infect. Dis. 13 (1994) 325-329
57. Brammer K.W., Farrow P.R., and Faulkner J.K. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 12 Suppl. 3 (1990) S318-S326
58. Branch R.A. Prevention of amphotericin B-induced renal impairment: A review on the use of sodium supplementation. Arch. Intern. Med. 148 (1988) 2389-2394
59. Brannon P., and Kiehn T.E. Large-scale clinical comparison of the lysis-centrifugation and radiometric systems for blood culture. J. Clin. Microbiol. 22 (1985) 951-954
60. Brannon P., and Kiehn T.E. Clinical comparison of lysis-centrifugation and radiometric resin systems for blood cultures. J. Clin. Microbiol. 24 (1986) 886-887
61. Braunstein H., and Tomasulo M. A quantitative study of the growth of Candida albicans in vented and unvented blood-culture bottles. Am. J. Clin. Pathol. 66 (1976) 87-90
62. Briegel J., Forst H., Spill B., Haas A., Grabein B., Haller M., Kilger E., Jauch K.W., Maag K., Ruckdeschel G., and Peter K. Risk factors for systemic fungal infections in liver transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis. 14 (1995) 375-382
63. Bross J., Talbot G.H., Maislin G., Hurwitz S., and Strom B.L. Risk factors for nosocomial candidemia: A case-control study in adults without leukemia. Am. J. Med. 87 (1989) 614-620
64. Bryan C.S., and McFarland J.A. Cryptococcal meningitis: Fatal marrow aplasia from combined therapy. JAMA 239 (1978) 1068-1069
65. Buchanan A.G., Riben P.D., Rayner E.N., Parker S.E., Ronald A.R., and Louie T.J. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: Correlation of colonization and clinical outcome. Clin. Invest. Med. 8 (1985) 139
66. Buchman T.G., Rossier M., Merz W.G., and Charache P. Detection of surgical pathogens by in vitro DNA amplification. Part I: Rapid identification of Candida albicans by in vitro amplification of a fungus-specific gene. Surgery 108 (1990) 338-346
67. Burchard K.W., Minor L.B., Slotman G.J., and Gann D.S. Fungal sepsis in surgical patients. Arch. Surg. 118 (1983) 217-221
68. Burgener-Kairuz P., Zuber J.-P., Jaunin P., Buchman T.G., Bille J., and Rossier M. Rapid detection and identification of Candida albicans and Torulopsis (Candida) glabrata in clinical specimens by species-specific nested PCR amplication of a cytochrome P-450 lanosterol-α-demethylase (LIAI) gene fragment. J. Clin. Microbiol. 32 (1994) 1902-1907
69. Burks L.C., Aisner J., Fortner C.L., and Wiernik P.H. Meperidine for the treatment of shaking chills and fever. Arch. Intern. Med. 140 (1980) 483-484
70. Burnie J.P., Odds F.C., Lee W., Webster C., and Williams J.D. Outbreak of systemic Candida albicans in intensive care unit caused by cross infection. Br. Med. J. 290 (1985) 746-748
71. Burnie J.P., and Williams J.D. Evaluation of the Ramco latex agglutination test in the early diagnosis of systemic candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 4 (1985) 98-101
72. Butler K.M., and Baker C.J. Candida: An increasingly important pathogen in the nursery. Pediatr. Clin. North Am. 35 (1988) 543-563
73. Calderone R.A., and Braun P.C. Adherence and receptor relationships of Candida albicans. Microbiol. Rev. 55 (1991) 1-20
74. Capek A., and Simek A. Content of ergosterol and the problem of transient resistance of dematophytes. Folia Microbiol. Prague 17 (1972) 239-240
75. Carroll K., Jeppson K., Reading J., and Reimer L. Factors influencing outcome in hospitalized patients with candidemia. Infect. Dis. Clin. Pract. 2 (1993) 268-271
76. Carver P.L., Berardi R.R., Knapp M.J., Rider J.M., Kauffman C.A., Bradley S.F., and Atassi M. In vivo interaction of ketoconazole and sucralfate in healthy volunteers. Antimicrob. Agents Chemother. 38 (1994) 326-329
77. Castaldo P., Stratta R.J., Wood R.P., Markin R.S., Patil K.D., Shaefer M.S., Langnas A.N., Reed E.C., Li S., Pillen T.J., and Shaw B.W. Clincal spectrum of fungal infections after orthotopic liver transplantation. Arch. Surg. 126 (1991) 149-156
78. Cauwenbergh G. Safety aspects of ketoconazole, the most commonly used systemic antifungal. Mycosis 32 (1989) 59-63
79. Cauwenbergh G., Degreef H., Heykants J., Woestenborghs R., Van Rooy P., and Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J. Am. Acad. Dermatol. 18 (1987) 263-268
80. Chia J.K.S., and McManus E.J. In vitro tumor necrosis factor induction assay for analysis of febrile toxicity with amphotericin B preparations. Antimicrob. Agents Chemother. 34 (1990) 906-908
81. Chin T.W.F., Loeb M., and Fong I.W. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob. Agents Chemother. 39 (1995) 1671-1675
82. Ching M.S., Raymond K., Bury R.W., Mashford M.L., and Morgan D.J. Absorption of orally administered amphotericin B lozenges. Br. J. Clin. Pharmacol. 16 (1983) 106-108
83. 19F nuclear magnetic resonance spectroscopy. Antimicrob. Agents Chemother. 33 (1989) 1939-1945
84. Christiansen K.J., Bernard E.M., Gold J.W.M., and Armstrong D. Distribution and activity of amphotericin B in humans. J. Infect. Dis. 152 (1985) 1037-1043
85. Clark J.M., Whitney R.R., Olsen S.J., Geroge R.J., Swerdel M.R., Kunselman L., and Bonner D.P. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother. 35 (1991) 615-621
86. Clements J.S., and Peacock J.E. Amphotericin B revisited: Reassessment of toxicity. Am. J. Med. 88 (1990) 22-27
87. Como J.A., and Dismukes W.E. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330 (1994) 263-272
88. Crane J.K., and Shih H.-T. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am. J. Med. 95 (1993) 445-446
89. Craven P.C. Tissue storage and clearance of amphotericin B. 20th Interscience Conference on Antimicrobial Agents and Chemotherapy (1980) (abstract No 111)
90. Craven, P. C., and Drutz, D. J. (1979). Tissue storage of amphotericin B and amphotericin B methyl ester aspartate. 19th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract no. 156)
91. Craven P.C., Ludden T.M., Druz D.J., Rogers W., Haegele K.A., and Skrdlant H.B. Excretion pathways of amphotericin B. J. Infect. Dis. 140 (1979) 329-341
92. Craven P.C., Graybill J.R., Jorgensen J.H., Dismukes W.E., and Levine B.E. High-dose ketoconazole for treatment of fungal infections of the central nervous system. Ann. Intern. Med. 98 (1983) 160-167
93. Crussell-Porter L.L., Rindone J.P., Ford M.A., and Jaskar D.W. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch. Intern. Med. 153 (1993) 102-104
94. Cutler T.E., Blair A.D., and Kelly M.R. Flucytosine kinetics in subjects with normal and impaired renal function. Clin. Pharmacol. Ther. 24 (1978) 332-342
95. Daneshmend T.K., and Warnock D.K. Clinical pharmacokinetics of systemic antifungal drugs. Clin. Phamacokinet. 8 (1983) 17-42
96. Daneshmend T.K., Warnock D.W., Ene M.D., Johnson E.M., Potten M.R., Richardson M.D., and Williamson P.T. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob. Agents Chemother. 25 (1984) 1-3
97. De Beule, K., Jacqmin, P., Van Peer, A., Stoffels, P., and Keytants, J. (1995). The pharmacokinetic rationale behind intravenous itraconazole. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract A75).
98. de Brabander M., Aerts F., van Cutsem J., Vanden Bossche H., and Borges M. The activity of ketoconazole in mixed cultures of leukocytes and Candida albicans. Sabourau- dia 18 (1980) 197-210
99. de Marie S., Janknegt R., and Bakker-Woudenberg I.A.J.M. Clinical use of liposomal and lipid-complexed amphotericin B. J. Antimicrob. Chemother. 33 (1994) 907-916
100. de Repentigny Marr L.D., Keller J.W., Carter A.W., Kuykendall R.J., Kaufman L., and Reiss E. Comparison of enzyme immunoassay and gas-liquid chromatography for the rapid diagnosis of invasive candidiasis in cancer patients. J. Clin. Microbiol. 21 (1985) 972-979
101. DeGregorio M.W., Lee W.M.F., and Ries C.A. Candida infections in patients with acute leukemia: Ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 50 (1982) 2780-2784
102. del Palacio A., Cuktara M.S., Ferro M., Pérez-Blazquez E., López-Sanda J.A., Roiz M.P., Carnevali D., and Noriega A.R. Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts. Mycoses 36 (1993) 193-199
103. DeLozier III J.B., Stratton C.W., and Potts III J.R. Rapid diagnosis of Candida sepsis in surgical patients. Am. Surg. 53 (1987) 600-602
104. DeMonaco H.J., and McGovern B. Transient asystole associated with amphotericin B infusion. Drug Intel. Clin. Pharm. 17 (1983) 547-548
105. Denning D.W., Donnelly J.P., Hellreigel K.K.P., Ito J., Martino P., and van't Wout J.W. Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: What is the state of the art. Chemotherapy 38 (1991) 43-49
106. Diasio R.B., Bennet J.E., and Myers C.E. Mode of action of 5-fluorocytosine. Biochem. Pharmacol. 27 (1978) 703-707
107. Dick J., Merz W., and Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob. Agents Chemother. 18 (1980) 158-163
108. Doebbeling, B. N., Hollis, R. J., Wenzel, R. P., Pfaller, M. A., and Reagan, D. R. (1992). Prospective evaluation of Candida hand carriage: Molecular typing of paired isolates. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract 261)
109. Donahue S.P., Greven C.M., Zuravleff J.J., Eller A.W., Nguyen M.H., Peacock J.E., Wagener M.M., and Yu V.L. Intraocular candidiasis in patients with candidemia: Clinical implications derived from a prospective multicenter study. Ophthalmology 101 (1994) 1302-1309
110. Douglas J.B., and Healy J.K. Nephrotoxic effects of amphotericin B, including renal tubular acidosis. Am. J. Med. 46 (1969) 154-162
111. Drouhet E., Mercier-Soncy L., and Montplaisir S. Sensibilite et resistance des levures pathogenes aux 5 flouropyrirnidines. I. Relation entre les phenotypes de resistance, le serotype de Candida albicans et I'ecologie de differentes especes de Candida dorigine humaine. Ann. Microbiol. (Paris) 126B (1985) 25-39
112. Drutz D.J., and Lehrer R.I. Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am. J. Med. Sci. 276 (1978) 77-92
113. Dukes C.D., and Perfect J.R. Amphotericin B-induced malignant hypertensive episodes. J. Infect. Dis. 161 (1990) 588
114. Dupont B., and Drouhet E. Cutaneous, occular and osteoarticular candidiasis in heroin addicts. J. Infect. Dis. 152 (1985) 577-591
115. Dupont B., and Drouhet E. Early experience with itraconazole in vitro and in patients: Pharmacokinetics studies and clinical results. Rev. Infect. Dis. 9 Suppl. l (1987) S43-S46
116. Dutcher J.D. The discovery and development of amphotericin B. Dis. Chest 54 Suppl. l (1968) 296-298
117. Ebden P., Neill P., and Farrow P.R. Sputum levels of fluconazole in humans. Antimicrob. Agents Chemother. 33 (1989) 963-964
118. Edwards Jr. J.E., Foos R.Y., Montgomerie J.Z., and Guze L.B. Ocular manifestations of Candida septicemia: Review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine 53 (1974) 47-75
119. Engelhard S., Stutman H.R., and Marks M.I. Interaction of ketoconazole with rifampin and isoniazid. N. Engl. J. Med. 311 (1984) 1681-1683
120. Eras P., Goldstein M.J., and Sherlock P. Candida infections of the gastrointestinal tract. Medicine 51 (1972) 367-379
121. Escuro R.S., Jacobs M., Gerson S.L., Machicao A.R., and Lazarus H.M. Prospective evaluation of a Candida antigen detection test for invasive candidiasis in immunocom- promised adult patients with cancer. Am. J. Med. 87 (1989) 621-627
122. Eubanks P.J., de Virgilio C., Klein S., and Bongard F. Candida sepsis in surgical patients. Am. J. Surg. 166 (1993) 617-620
123. Faix R.G. Systemic Candida infections in infants in intensive care nurseries: High incidence of central nervous system involvement. J. Pediatr. 105 (1984) 616-622
124. Faix R.G. Invasive neonatal candidiasis: Comparison of albicans and parapsilosis infection. Pediatr. Infect. Dis. J. 11 (1992) 88-93
125. Fielding R.M., Smith P.C., Wang L.H., Porter J., and Guo L.S. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation in rats. Antimicrob. Agents Chemother. 35 (1991) 1208-1213
126. Fielding R.M., Singer A.W., Wang L.H., Babbar S., and Guo L.S.S.S. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of arnphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. 36 (1992) 299-307
127. Fields Jr. B.T., Bates J.H., and Abernathy R.S. Amphotericin B serum concentrations during therapy. Appl. Microbiol. 19 (1970) 955-959
128. Filler S.G., Crislip M.A., Mayer C.L., and Edwards J.E.J. Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthal- mitis in rabbits. Antimicrob. Agents Chemother. 35 (1991) 288-292
129. 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob. Agents Chemother. 37 (1993) 1270-1277
130. Fisher M.A., Shen S.-H., Haddad J., and Tarry W.F. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother. 33 (1989) 1443-1446
131. Fisher M.A., Talbot G.H., Maislin G., McKeon B.P., Tynan K.P., and Strom B.L. Risk factors for amphotericin B-associated nephrotoxicity. Am. J. Med. 87 (1989) 547-552
132. Foisy, M. M., Nix, D., Middleton, E., Kotas, T., and Syrnonds, W. T. (1995). The effects of single dose fluconazole (SD FLU) versus multiple dose fluconazole (MD FLU) on the pharmacokinetics (PK) of theophylline (THL) in young healthy volunteers. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract A35)
133. Foulds G., Brennan D.R., Wajszczuk C., Catanzaro A.C.G.D., Knopf W., Rinaldi M., and Weidler D.J. Fluconazole penetration in cerebrospinal flaid in humans. J. Clin. Pharmacol. 28 (1988) 3636-3666
134. Foulds G., Wajszczuk D.J., Weidler K.J., Garg D.J., and Gibson P. Steady state parenteral kinetics of fluconazole in man. Ann. NY Acad. Sci. 544 (1988) 427-430
135. Fraser V.J., Jones M., Dunkel J., Storfer S., Medoff G., and Dunagan W.C. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality. Clin. Infect. Dis. 15 (1992) 414-421
136. Fujita S.-I., and Hashimoto T. Detection of serum Candida antigens by enzyme-linked immunosorbent assay and a latex agglutination test with anti-Candida albicans and anti-Candida krusei antibodies. J. Clin. Microbiol. 30 (1992) 3132-3137
137. Fujita S.-I., Lasker B.A., Lott T.J., Reiss E., and Morrison C.J. Microtitration plate enzyme immunoassay to detect PCR-amplified DNA from Candida species in blood. J. Clin. Microbiol. 33 (1995) 962-967
138. Fung J.C., Donta S.T., and Tilton R.C. Candida detection system (CAND-TEC) to differentiate between Candida albicans colonizations and disease. J. Clin. Microbiol. 24 (1986) 542-547
139. Gaines J.D., and Remington J.S. Disseminated candidiasis in the surgical patient. Surgery 72 (1972) 730-736
140. Gaines J.D., and Remington J.S. Diagnosis of deep infection with Candida: A study of Candida precipitins. Arch. Intern. Med. 132 (1973) 699-702
141. Galgiani J.N., Stevens D.A., Graybill J.R., Dismukes W.E., and Cloud G.A. Ketoconazole therapy of progressive coccidioidomycosis: Comparison of 400- and 800-mg doses and observations at higher doses. Am. J. Med. 84 (1988) 603-610
142. Gallis H.A., Drew R.H., and Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12 (1990) 308-329
143. Gantz N.M., Medeiros A.A., Swain J.L., and O'Brien T.F. Vacuum blood culture bottles: Inhibiting growth of Candida and fostering growth of Bacteroides. Lancet 2 (1974) 1174-1176
144. Garcia-Hermoso D., Dromer F., Improvisi L., Provost F., and DuPont B. Fluconazole concentrations in saliva from AlDS patients with oropharyngeal candidosis refractory to treatment with fluconazole. Antimicrob. Agents Chemother. 39 (1995) 656-660
145. Gascoigne E.W., Barton G.J., Michaels M., Meuldermans W., and Heykants J. The kinetics of ketoconazole in animals and man. Clin. Res. Rev. 1 (1981) 177-187
146. Geiger A.M., Foxman B., and Sobel J.D. Chronic vulvovaginal candidiasis: Characteristics of women with Candida albicans, Candida glabrata and no Candida. Genitourin. Med 71 (1995) 304-307
147. Gentry L.O., McNitt T.R., and Kaufman L. Use and value of serologic tests for the diagnosis of systemic candidiasis in cancer patients: A prospective study of 146 patients. Curr. Microbiol. 1 (1978) 239-242
148. Gentry L.O., Wilkinson I.D., Lea A.S., and Price M.F. Latex agglutination test for detection of Candida antigen in patients with disseminated disease. Eur. J. Clin. Microbiol. Infect. Dis. 2 (1983) 122-128
149. Ghannoum M.A., Rex J.H., and Galgiani J.N. Susceptibility testing of fungi: Current status of correlation of in vitvo data with clinical outcome. J. Clin. Microbiol. 34 (1996) 489-495
150. Gigliotti F., Shenep J.L., Lott L., and Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J. Infect. Dis. 156 (1987) 784-789
151. Gill B.J., Zierdt C.H., Wu T.C., Stock F., Pizzo P.A., and MacLowry J.D. Comparison of lysis-centrifugation with lysis-filtration and a conventional unvented bottle for blood cultures. J. Clin. Microbiol. 20 (1984) 937-942
152. Gold J.W., Wong M.B., Bernard T.E., Kiehn T.E., and Armstrong D. Serum arabinitol concentration and arabinitokreatinine ration in invasive candidiasis. J. Infect. Dis. 147 (1983) 504-513
153. Goodman J.L., Winston D.J., Greenfield R.A., Chandrasekar P.H., Fox B., Kaizer H., Shadduck F.K., Shea T.C., Stiff P., Friedman D.J., Powderly W.G., Silber J.L., Horowitz H., Lichtin A., Wolff S.N., Mangan K.F., Silver S.M., Weisdorf D., Ho W.G., Gilbert G., and Buell D. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326 (1992) 845-851
154. Goodrich J.M., Reed E.C., Mori M., Fisher L.D., Skerrett S., Damdliker P.S., Klis B., Counts G.W., and Meyers J.D. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J. Infect. Dis. 164 (1991) 731-740
155. Gradon J.D., and Sepkowithz D.V. Fluconazole-associated acute adrenal insufficiency. Postgrad. Med. J. 67 (1991) 1084-1085
156. Graninger W., Presteril E., Schneeweiss B., Teleky B., and Georgopoulos A. Treatment of Candida albicans fungaemia with fluconazole. J. Infect. 16 (1993) 133-146
157. Grant S.M., and Clissold S.P. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37 (1989) 310-344
158. Grant S.M., and Clissold S.P. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39 (1990) 877-916
159. Grasela T.H., Gooewin S.D., Walawander M.K., Cramer R.L., and Fuhs D.W. Prospective surveillance of intravenous amphotericin B use patterns. Pharmacotherapy 10 (1990) 341-348
160. Graybill, J. R., Vazquez, J., Darouiche, R. O., Morhart, R., Moskovitz, B. L., and Mallegol, I. (1995), Itraconazole oral solution versus fluconazole treatment of oropharyngeal candi-diasis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract 1220)
161. Greenfield R.A., Bussey M.J., Stephens J.L., and Jones J.M. Serial enzyme-linked immunosorbent assays for antibody to Candida antigens during induction chemotherapy for acute leukemia. J. Infect. Dis. 148 (1983) 275-283
162. Gross M.H., Fulkerson W.J., and Moore J.O. Prevention of amphotericin B-induced rigors by dantrolene. Arch. Intern. Med. 146 (1986) 1587-1588
163. Guerra-Romero L., Edson T.S., Cockerill III F.R., Horstemeier C.D., and Roberts G.D. Comparison of DuPont Isolator and Roche Septi-chek for detection of fungemia. J. Clin. Microbiol. 25 (1987) 1623-1625
164. Guinan M.E., Portas M.T., and Hill H.R. The Candida precipitin test in an immunosuppressed population. Cancer 43 (1979) 299-302
165. Guinet R., Chanas J., Goullier A., Bennefoy G., and Ambroise-Thomas P. Fatal septicemia due to amphotericin B-resistant Candida Iusituniae. J. Clin. Microbiol. 18 (1983) 443-444
166. Gutiérrez J., Maroto C., Piidrorla G., Martin E., and Perez J.A. Circulating Candida antigens and antibodies: Useful markers of candidemia. J. Clin. Microbiol. 31 (1993) 2550-2552
167. Hamilton-Miller J.M.T. A comparative in vitro study of amphotericin B, clotrimazole and 5-fluorocytosine aginst clinically isolated yeasts. Sabouraudia 10 (1982) 276-283
168. Hann I.M., Prentice H.G., Corringham R., Blacklock H.A., Keaney M., Shannon M., Noone P., Gascoigne E., Fox J., Boesen E., Szawatkowski M., and Hoffbrand A.V. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1 (1982) 826-829
169. Hann I.M., Prentice H.G., Keaney M., Corringham R., Blacklock H.A., Fox J., Gascoigne E., and van Cutsem J. The pharmacokinetics of ketoconazole in severely immunocompromised patients. J. Antimicrob. Cbemother. 10 (1983) 489-496
170. Hansen R.M., Reinerio N., Shonle P.G., Abrams R.A., Ritch P.S., Libnoch J.A., and Anderson T. Ketoconazole in the prevention of candidiasis in patients with cancer: A prospective, randomized, controlled, double-blind study. Arch. Intern. Med. 147 (1987) 710-712
171. Hanson L.H., and Stevens D.A. Comparison of antifungal activity of amphotericin B desoxycholate suspension with that of amphotericin B cholesteryl sulfate clloidal dispersion. Antimicrob. Agents Chemother. 36 (1992) 486-488
172. Harder E.J., and Hermans P.E. Treatment of fungal infections with flucytosine. Arch. Intern. Med. 135 (1975) 231-237
173. Hardin T.C., Graybill J.R., Fetchichk R., Woestenborghs R., Rinaldi M.G., and Kuhn J.G. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob. Agents Chemother. 32 (1988) 1310-1313
174. Harvey R.L., and Myers J.P. Nosocomial fungemia in a large community teaching hospital. Arch. Intern. Med. 147 (1987) 2117-2120
175. Hawser S.P., and Douglas L.J. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 39 (1995) 2128-2131
176. Hay R.J. Riskhenefit ratio of modern antifungal therapy: Focus on hepatic reactions. J. Am. Acad. Dermatol. 29 (1993) S50-SS4
177. Hazen K.C., and Hazen B.W. Hydrophobic surface protein masking by the opportunistic fungal pathogen Candida albicans. Infect. Immun. 60 (1992) 1499-1508
178. Heel R.C. Ketoconazole in the management of fungal diseases. In: Levine H.B. (Ed). "Ketoconazole in the Management of Fungal Infections" (1982), ADIS Press, New York
179. Heel R.C., Brogden R.N., Carmine A., Morley P.A., Speight T.M., and Avery G.S. Ketoconazole: A review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23 (1982) 1-36
180. Heinemann V., Kahny B., Debus K., Wachholz K., and Jehn V. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transplant. 14 (1994) S8-S9
181. Hernández J.A., Gonazalez-Moreno M., Llibre J.M., Aloy A., and Casan J.M. Candidal mitral endocarditis and long-term treatment with fluconazole in a patient with human immunodeficiency virus infection. Clin. Infect. Dis. 15 (1992) 1062-1063
182. Hertenstein B., Kern W.V., Schmeiser T., Stefanic M., Bunjes D., Wiesneth M., Novotny J., Heimpel H., and Arnold R. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann. Hematol. 68 (1994) 21-26
183. Heykants J., Michiels M., Meuldermans W., Monbaliu J., Lavrijsen K., Van Peer A., Levron J.C., Woestenborghs R., and Cauwenbergh G. The pharmacokinetics of itraconazole in animals and man: An overview. In: Fromtling R.A. (Ed). "Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents" (1987), J. R. Prous Science Publishers, Barcelona, Spain 1-29
184. Heykants J., Van Peer A., Van de Velde V., Van Rooy P., Meuldermans W., Lavrijsen K., Wowetenborgh R., Van Cutsen J., and Cauwenbergh G. The clinical pharmacokinetics of itraconazole: An overview. Mycoses 32 (1989) 67-87
185. Heyl T. Treatment of chromomycosis with itraconazole. Br. J. Dermatol. 112 (1985) 728-729
186. Hill G.J. Changes in renal morphology. Ann. Intern. Med. 61 (1964) 349-354
187. Ho Y.M., Teoh-Chan M.H.N., Yue P.C.K., and Huang C.T. Indirect immunofluo-rescence assay for antibody to germ tube of Candida albicans-A new diagnostic test. J. Clin. Pathol. 29 (1976) 1007-1010
188. Honig P.K., and Cantilena L.R. Ketoconazole and fluconazole drug interactions. Arch. Intern. Med. 154 (1994) 1038-1039
189. Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mullin J.C., and Cantilena J.R. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardio-graphic consequences. JAMA 269 (1993) 1513-1518
190. Honig P.K., Wortham D.C., Zamani K., Mullin J.C., Conner D.P., and Cantilena L.R. The effect of fluconazole on the steady-state pharmacokinetics and electrocardio-graphic pharmacodynamics of terfenadine in humans. Clin. Pharmacol. Ther. 53 (1993) 630-636
191. Hopfer R.L., Orengo A., Chesnut S., and Wenglar M. Radiometric detection of yeast in blood cultures of cancer patients. J. Clin. Microbiol. 12 (1980)
192. Hopfer R.L., Walden P., Setterqiost S., and Highsmith W.E. Detection and differentiation of fungi in clinical specimens using polymerase chain reaction (PCR) amplification and restriction enzyme analysis. J. Med. Vet. Mycol. 31 (1993) 65-75
193. Hopfer R.L., Mills K., Mehta R., Lopez-Berstein G., Fanstein V., and Juliano R.L. In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob. Agents Chemother. 25 (1984) 387-389
194. Horn R., Wong B., Kiehn T.E., and Armstrong D. Fungemia in a cancer hospital: Changing frequency, earlier onset, and results of therapy. Rev. Infect. Dis. 7 (1985) 646-655
195. Horowitz E.A., Preheim T.B., Neumann T.V., and Bittner M.J. Hepatotoxicity due to amphotericin B. Infect. Dis. Clin. Pract. 1 (1992) 123-125
196. Horsburgh C.R., Kirkpatrick C.H., and Teutsch C.B. Ketoconazole and the liver. Lancet 1 (1982) 860
197. Hsuchen C.-C., and Feingold D.S. Selective membrane toxicity of the polyene antibiotics: Studies on natural membranes. Antimicrob. Agents Chemother. 4 (1973) 316-319
198. Hughes W.T. Systemic candidiasis: A study of 109 fatal cases. Pediatr. Infect. Dis. J. 1 (1982) 11-18
199. Humphrey M.J., Jevons S., and Tarbit M.H. Pharmacokinetic evaluation of UK- 49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents Chemother. 28 (1985) 648-653
200. Iwen P.C., Kelly D.M., Reed E.C., and Hinrichs S.H. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin. Infect. Dis. 20 (1995) 342-347
201. Jacobson M.A., Hanks D.K., and Ferrell L.D. Fatal acute hepatic necrosis due to fluconazole. Am. I. Med. 96 (1994) 188-190
202. Janknegt R., de Marie S., Bakker-Woundenberg I.A.J.M., and Crommenlin D.J.A. Liposomal and lipid formulations of amphotericin B. Clin. Phurrnucokinet. 23 (1992) 279-291
203. Jarvis W.R. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin. Infect. Dis. 20 (1995) 1526-1530
204. Jones J.M. Kinetics of antibody responses to cell wall mannan and a major cytoplasmic antigen of Candida albicans in rabbits and humans. J. Lab. Clin. Med. 96 (1980) 845-860
205. Jones J.M. Granulomatous hepatitis due to Candida albicans in patients with acute leukemia. Ann. Intern. Med. 94 (1981) 475-477
206. Jund R., and Lacroute F. Genetic and physiological aspects of resistance to S-flUOrO- pyrimidines in Saccharomyces cerevisiae. J. Bacteriol. 102 (1970) 607-615
207. Jund R., and Lacroute F. Genetique et physiologie de le resistance aux 5-fluoropyrimidines chez Sacchuromyces cerevisiae. Bull. Soc. Franc. Mycol. Med. 3 (1974) 5-8
208. Kahn F.W., and Jones J.M. Latex agglutination tests for detection of Candida antigens in sera of patients with invasive candidiasis. J. Infect. Dis. 153 (1986) 579-585
209. Kan V.L. Polymerase chain reaction for the diagnosis of candidemia. J. Infect. Dis. 168 (1993) 779-783
210. Kandrotas R.J., Slaughter R.L., Brass C., and Jusko W.J. Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. Clin. Phurmucol. Ther. 42 (1987) 465-470
211. Karabinis A., Hill C., Leclerq B., Tancrsde C., Baume D., and Andremont A. Risk factors for candidemia in cancer patients: A case-control study. J. Clin. Microbiol. 26 (1988) 429-432
212. Karyotakis N.C., and Anaissie E.J. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida ltrsituniue and Candida krusei infection in neutropenic mice. Antimicrob. Agents Chemother. 38 (1994) 2660-2662
213. Kauffman C.A., Bradley S.F., Ross S.C., and Weber D.R. Hepatosplenic candidiasis: Successful treatment with fluconazole. Am. I. Med. 91 (1991) 137-141
214. Kerkering T.M., Espinel-Ingroff A., and Shadomy S. Detection of Candida antigenemia by counterimmunoelectrophoresis in patients with invasive candidiasis. J. Infect. Dis. 140 (1979) 659-664
215. Kerridge D., and Whelan W.L. The polyene macrolide antibiotics and 5-fluorocposine: Molecular actions and interactions. In: Trinci A.P.J., and Ryley J.F. (Eds). "Mode of Action of Antifungal Agents" (1984), Cambridge University Press, Cambridge 343-375
216. Kiehn F.W., Wong E.B., Edwards F.F., and Armstrong D. Comparative recovery of bacteria and yeast from lysis-centrifugation and a conventional blood culture system. I. Clin. Microbiol. 18 (1983) 300-304
217. Kiehn T.E., Capitolo C., Mayo J.B., and Armstrong D. Comparative recovery of fungi from biphasic and conventional blood culture media. J. Clin. Microbiol. 14 (1981) 681-683
218. Klein J.J., and Watanakunakorn C. Hospital-acquired fungemia: Its natural course and clinical significance. Am. J. Med. 67 (1979) 51-58
219. Knaus W.A., Draper E.A., Wagner D.P., and Zimmerman J.E. APACHE II: A severity of disease classification system. Crit. Cure Med. 13 (1985) 818-829
220. Komshian S.V., Uwaydah A.K., Sobel J.D., and Crane L.R. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: Frequency, characteristics, and evaluation of factors influencing outcome. Rev. Infect. Dis. 11 (1989) 379-390
221. Kozinn P.J., Taschojian C.L., Goldberg P.K., Protzmann W.P., MacKenzie D.W.R., Remington J.S., Anderson S., and Seelig M.S. Efficiency of serologic tests in the diagnosis of systemic candidiasis. Am. J. Clin. Pathol. 70 (1978) 893-989
222. Kramer M.R., Marshall S.E., Denning D.W., Keogh A.M., Tucker R.M., Galgiani J.N., Lewiston N.J., Stevens D.A., and Theodore J. Cyclosporine and itracona-zole interaction in heart and lung transplant recipients. Ann. Intern. Med. 113 (1990) 327-329
223. Krause W., Matheis H., and Wulf K. Fungemia and funguria after oral administration of Candida albicans. Lancet 1 (1969) 598-599
224. Kwon-Chung K.J., and Bennett J.E. "Medical Mycology" (1992), Lea & Febiger, Philadelphia
225. Lamp K. Drug interactions in AIDS patients. Infect. Dis. Alert 1 (1994) 118-120 May
226. Lancaster D.J., Palte S., and Ray D. Recombinant human erythropoietin in the treatment of anemia in AIDS patients receiving concomitant amphotericn B and zidovud-ine. J. Acq. Immune Defic. Synd. Hum. Retrovirol. 6 (1993) 533-534
227. Law E.J., Kin O.J., Stieritz D.D., and MacMilllian B.G. Experience with systemic candidiasis in the burned patient. J. Trauma 12 (1972) 543-552
228. Lawrence R.M., Hoeprich P.D., Jagdis F.A., Monji N., Huston A.C., and Schaffner C.P. Distribution of doubly radiolabelled amphotericin B methyl ester and ampho-tericin B in the nonhuman primate, Macaca mulatta. J. Antimicrob. Cbemother. 6 (1980) 241-249
229. Lazar J.D., and Wilner K.D. Drug interactions with fluconazole. Rev. Infect. Dis. 12 Suppl. 3 (1990) S327-S333
230. Lecciones J.A., Lee J.W., Navarro E.E., Witebsky F.G., Marshall D., Steinberg S.M., Pizzo P.A., and Walsh T.J. Vascular catheter-associated fungemia in patients with cancer: Analysis of 155 episodes. Clin. Infect. Dis. 14 (1992) 875-883
231. Lemieux C., Germain G., Vincelette J., Kaufman L., and DeRepentigny L. Collaborative evaluation of antigen detection by a commercial latex agglutination test and enzyme immunoassay in the diagnosis of invasive candidiasis. J. Clin. Microbiol. 28 (1990) 249-253
232. Levin J., Bernard D.B., Idelson B.A., Farnham H., Saunders C., and Sugar A.M. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: Successful treatment with fluconazole, a new orally active antifungal agent. Am. J. Med. 86 (1989) 825-829
233. Levison D.J., Silcox D.C., Rippon J.W., and Thomsen S. Septic arthritis due to nonencapsulated Cryptococcus neoformans with coexisting sarcoidosis. Arthritis Rheum. 17 (1974) 1037-1047
234. Lim S.G., Sawyerr A.M., Hudson M., Sercombe J., and Pounder R.E. Short report: The absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment. Pharmacol. Therapeut. 7 (1993) 317-321
235. Lin A.C., Goldwasser E., Bernard E.M., and Chapman S.W. Amphotericin B blunts erythropoietin response to anemia. J. Infect. Dis. 161 (1990) 348-351
236. Lister, J. (1994). Amphotericin B lipid complex in the management of serious systemic mycoses in patients intolerant to amphotericin B therapy. 36th Annual Meeting and Exposition of the American Society of Hematology (abstract 1209)
237. Lorber B., Cutler C., and Barry W.E. Allergic rash due to amphotericin B. Ann. Intern. Med. 84 (1976) 54
238. Louie A., Baltch A.L., Franke M.A., Smith R.P., and Gordon M.A. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumor necrosis factor alpha: An effect that is attenuated by pentoxifyline, liposomal vesicles and dexamethasone. J. Antimicrob. Chernother. 34 (1994) 975-987
239. Louria D.B. Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Antibiot. Med. Clin. Ther. 5 (1958) 295-301
240. Louria D.B., Stiff D.F., and Bennet B. Disseminated moniliasis in the adult. Medicine 41 (1962) 307-337
241. Lowder J.N., Lazarus H.M., and Herzig R.H. Bacteremias and fungemias in oncologic patients with central venous catheters: Changing spectrum of infection. Arch. Intern. Med. 142 (1982) 1456-1459
242. MacGregor R.R., Bennett J.E., and Erslev A.J. Erythropoietin concentration in amphotericin B-induced anemia. Antimicrob. Agents Chemother. 14 (1978) 270-273
243. Maddux M.S., and Barriere S.L. A review of complications of amphotericin B therapy: Recommendations for prevention and management. Drug Intell. Clin. Pharm. 14 (1980) 177-181
244. Maki D.G., Weise C.E., and Sarafin H.W. A semiquantitative culture method for identifying intravenous-catheter related infection. N. Engl. J. Med. 296 (1977) 1305-1309
245. Makimura K., Murayama S.Y., and Yamaguchi H. Detection of a wide range of medically important fungi by the polymerase chain reaction. J. Med. Microbiol. 40 (1993) 358-364
246. Maksymiuk A.W., Thonprasert S., Hopfer R., Luna M., Fainstein V., and Bodey G.P. Systemic candidiasis in cancer patients. Am. J. Med. 77 4D (1984) 20-27
247. Manez R., Martin M., Raman V., Silverman D., Jain A., Warty V., Gonzalez-Pinto I., Kusne S., and Starzl T.E. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 57 (1994) 1521-1523
248. Mannisto P.T., Mantayla S., Nykanen S., Lamminsivy U., and Ottola P. Impairing effect of food on ketoconazole absorption. Antimicrob. Agents Chemother. 21 (1982) 730-733
249. Marriott M.S., and Richardson K. The discovery and mode of action of fluconazole. In: Fromtling R.A. (Ed). "Recent Trends in the Discovery, Development, and Evaluation of Antifungal Agents" (1987), J. R. Prous Science Publishers, Barcelona 81-92
250. Marsh P.K., Tally F.P., Kellum J., Gallow A., and Gorbach S.L. Candida infections in surgical patients. Ann. Surg. 198 (1983) 42-47
251. Martino P., Girmenia C., Venditti M., Micozzi A., Santili S., Burgio V.L., and Mandelli F. Candida colonization and systemic infection in neutropenic patients. Cancer 64 (1989) 2030-2034
252. Martino P., Girmenia C., Micozzi A., Raccah R., Gentile G., Venditto M., and Mandelli F. Fungemia in patients with leukemia. Am. J. Med. Sci. 306 (1993) 225-232
253. Martino P., Girmenia C., Micozzi A., De Bernardis F., Boccanera M., and Cassone A. Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. Eur. J. Clin. Microbiol. Infect. Dis. 13 (1994) 797-804
254. McCurdy D.K., Frederic M., and Elkinton J.R. Renal tubular acidosis due to amphotericin B. N. Engl. J. Med. 278 (1968) 124-131
255. McNulty R.M., Lazor J.A., and Sketch M. Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy. Clin. Pharm. 8 (1989) 222-225
256. McQuillen D.P., Zingman B.S., Meunier F., and Levitz S.M. Invasive infections due to Candida krusei: Report of ten cases of fungemia that include three cases of endophthalmitis. Clin. Infect. Dis. 14 (1992) 472-478
257. Medoff G. The mechanism of action of amphotericin B. In: Van den Bossche H. (Ed). "International Symposium on Aspergillus and Aspergillosis" (1987), Plenum Press, Antwerpen, New York 161-164
258. Medoff G., Dismukes W.E., Meade R.H., and Moses J.M. A new therapeutic approach to Candida infections: A preliminary report. Ann. Intern. Med. 130 (1972) 241-245
259. Merz W.G. Candida lusituniue: Frequency of recovery, colonization, infection, and amphotericin B resistance. J. Clin. Microbiol. 20 (1984) 1194-1195
260. Merz W.G., and Sanford G.R. Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J. Clin. Microbiol. 9 (1979) 677-680
261. Merz W.G., Karp J.E., Schron D., and Saral R. Increased incidence of fungemia caused by Candida krusei. J. Clin. Microbiol. 24 (1986) 581-584
262. Metroka C.E., McMechan M.F., Andrada R., Laubenstein L.J., and Jacobus D.P. Failure of prophylaxis with dapsone in patients taking dideoxyinosine [Letter]. N. Engl. J. Med. 325 (1991) 737
263. Meunier F., Prentice H.G., and Ringden O. Liposomal amphotericin B (AmBisome): Safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28 (1991) 83-91
264. Meunier R., Aoun A., and Bitar N. Candidemia in immunocompromised patients. Clin. Infect. Dis. 14 (1992) S120-S125
265. Meunier-Carpentier F., and Armstrong D. Candida antigenemia as detected by passive hemagglutination inhibition in patients with disseminated candidiasis or Candida colonization. J. Clin. Microbiol. 13 (1981) 10-14
266. Meunier-Carpentier F., Kiehn T.E., and Armstrong D. Fungemia in the imrnunocompromised host. Am. J. Med. 71 (1981) 363-370
267. Meyer R., and Axelrod J.A. Fatal aplastic anemia resulting from 5-fluorocytosine. JAMA 228 (1974) 1573
268. Miyakawa Y., Mabuchi T., Kagaya K., and Fukazawa Y. Isolation and characterization of a species-specific DNA fragment for detection of Candida albicans by polymerase chain reaction. J. Clin. Microbiol. 30 (1992) 894-900
269. Miyazaki T., Kohno S., Mitsutake K., Masaki S., Tanaka K., Ishikawa N., and Hara K. Plasma (1 → 3)-β-D glucan and fungal anrigenenia in patients with candidemia, aspergillosis and cryptococcosis. J. Clin. Microbiol. 33 (1995) 3115-3118
270. Monheit J.E., Cowan D.F., and Moore D.G. Rapid detection of fungi in tissues using calcofluor white and fluorescence microscopy. Arch. Pathol. Lab. Med. 108 (1984) 616-618
271. Moreno F., Hardin T.C., Rinaldi M.G., and Graybill J.R. Itraconazole-didanosine excipient interaction. JAMA 269 (1993) 1508
272. Morgan D.J., Ching M.S., Raymond K., Bury R.W., Mashford M.L., Kong B., Sabto J., Furr F.W., and Somogyi A.A. Elimination of amphotericin B in impaired renal function. Clin. Pharmacol. Ther. 34 (1983) 248-253
273. Munoz P., Bernaldo de Quiros J.C.L., Berenguer J., Rodriguez Creixems M., Picazo J.J., and Bouza E. Impact of the BACTEC NR system in detecting Candida fungemia. J. Clin. Microbiol. 28 (1990) 639-641
274. Munoz P., Moreno S., Berenguer J., Bernaldo de Quiros J.C.L., and Bouza E. Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome. Arch. Intern. Med. 151 (1991) 1020-1021
275. Murray H.W. Allergic reactions to amphotericin B [Letter]. N. Engl. J. Med. 290 (1974) 30-32
276. Muther T.S., and Bennett W.M. Peritoneal clearance of amphotericin B and 5- fluorocytosine. West. J. Med. 133 (1980) 157-160
277. Myerowitz R.L., Pazin G.J., and Allen C.M. Disseminated candidiasis: Changes in incidence, underlying diseases and pathology. Am. J. Clin. Pathol. 68 (1977) 29-38
278. Narang P.K., Trapnell C.B., Schoenfelder J.R., Lavelle J.P., and Bianchine J.R. Fluconazole and enhanced effect of rifabutin prophylaxis. N. Engl. J. Med. 330 (1994) 1316-1317
279. Navarro D., Monzonis E., Lopez-Ribot J.L., Sepulveda P., Casanova M., Nogueira J.M., and Martinez J.P. Diagnosis of systemic candidiasis by enzyme immunoassay detection of specific antibodies to mycelial phase cell wall and cytoplasmic candidal antigens. Eur. J. Clin. Microbiol. Infect. Dis. 12 (1993) 839-846
280. Ness M.J., Vaughan W.P., and Woods G.L. Candida antigen latex test for detection of invasive candidiasis in immunocompromised patients. J. Infect. Dis. 159 (1989) 495-502
281. Neuhaus G., Pavic N., and Pletscher M. Anaphylactic reaction after oral fluconazole. Br. Med. J. 37 (1991) 25-27
282. Neuvonen P.J., and Suhonen R. Itraconazole interacts with feldipine. J. Am. Acad. Dermatol. 33 (1995) 133-134
283. Nguyen M.H., Peacock J.E., Tanner Jr. D.J., Morris A.J., Nguyen M.L., Snydman D.R., Wagener M.M., and Yu V.L. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch. Intern. Med. 155 (1995) 2429-2434
284. Nomura J., and Ruskin J. Failure of therapy with fluconazole for candidal endophthal-mitis. Clin. Infect. Dis. 17 (1993) 888-889
285. Odds F.C. "Candida and Candidosis" (1988), Bailliere Tindall, London
286. Odds F.C., and Evans E.G.V. Distribution of pathogenic yeast and humoral antibodies to Candida among hospital inpatients. J. Clin. Pathol. 33 (1980) 750-756
287. Odds F.C., Cheesman S.L., and Abbott A.B. Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. J. Antimicrob. Chemother. 18 (1986) 473-478
288. Oldfield E.C., Garst P.D., Hostettler C., White M., and Samuelson D. Randomized, double-blind trial of 1-versus 4-hour amphotericin B infusion durations. Antimicrob. Agents Chemother. 34 (1990) 1402-1406
289. Olkkola K.T., Backman J.T., and Neuvonen P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55 (1994) 481-485
290. Pappagianis D., Collins M.S., Hector R., and Remington J. Development of resistance to amphotericin B in Candida Iusituniae infecting a human. Antimicrob. Agents Chemother. 16 (1979) 123-126
291. Pappas P.G., Kauffman C.A., Perfect J., Johnson P.C., McKinsey D.M., Bamberger D.M., Hamill R., Sharkey P.K., Chapman S.W., and Sobel J.D. Alopecia associated with fluconazole therapy. Ann. Intern. Med. 123 (1995) 354-357
292. Patterson R.M., and Ackerman G.L. Renal tubular acidosis due to amphotericin B nephrotoxicity. Arch. Intern. Med. 127 (1981) 241-254
293. Pennington J.E., Block E.R., and Reynolds H.Y. 5-Fluorocytosine and amphotericn B in bronchial secretions. Antimicrob. Agents Chemother. 6 (1974) 324-326
294. Perfect J.R., and Durack D.T. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob. Agents Chemother. 28 (1985) 751-755
295. Perry C.M., Whittington R., and McTavish D. Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis. Drugs 49 (1995) 984-1006
296. Pfaller M., Cabezudo I., Koontz F., Bale M., and Gingrich R. Predictive value of surveillance cultures for systemic infection due to Candida species. Eur. J. Clin. Microbiol. Infect. Dis. 6 (1987) 628-633
297. Phillips P., Dowd A., Jewesson P., Radigan G., Tweeddale M.G., Clarke A., Geere I., and Kelly M. Nonvalue of antigen detection immunoassays for diagnosis of candidemia. J. Clin. Microbiol. 28 (1990) 2320-2326
298. Phillips, P., Shafran, S., Garber, G., Rotstein, C., Smaill, F., Williams, K., Singer, J., Ioannou, S., and Canadian Candidemia Study Group (1995), Fluconazole (FLU) versus amphotericin B (AMB) for candidemia in non-neutropenic patients: A multicenter randomized trial. 35th lnterscience Conference on Antimicrobial Agents and Chemotherapy (abstract LM20)
299. Piens M.A., Guyotat D., Archimbaud E., Plotton C., Maupas J., Mojon M., and Fiere D. Evaluation of a Candida antigen detection test (CAND-TEC) in the diagnosis of deep candidiasis in neutropenic patients. Eur. J. Cancer Clin. Oncol. 24 (1988) 1655-1659
300. Pierce A.M., Pierce H.D., Unray Jr. A.M., and Oehlschlager A.C. Lipidcomposition and polyene antibiotic resistance of Candida ulbicuns mutants. Can. J. Biochem. 56 (1978) 135-142
301. Pittet D., Monod M., Surer P.M., Frenk E., and Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann. Surg. 220 (1994) 751-758
302. Pizzo P.A., Robichaud K.J., Gill F.A., and Witebsky F.G. Empiric antibiotics and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am. J. Med. 72 (1982) 101-111
303. Plouffe J.F., Brown D.G., Silva J., Eck T., Stricof R.L., and Fekety F.R. Nosocomial outbreak of Candida parapsilosis fungemia related to intravenous infusions. Arch. Intern. Med. 137 (1977) 1686-1689
304. Polak A. Pharmacokinetics of amphotericin B and flucytosine. Postgrad. Med. J. 55 (1979) 667-670
305. Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillo- sis and wangiellosis in mice. Chemotherapy 33 (1987) 381-395
306. Polak A., and Scholer J.H. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy 21 (1975) 113-130
307. Polak A., Eschenhof E., Fernex M., et al. Metabolic studies with S-fluorocytosine-6-14C in mouse, rat, rabbit, dog and man. Chemotherapy 22 (1976) 137-153
308. Pont A., Graybill R., and Craven P.C. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch. Intern. Med. 144 (1984) 2150-2153
309. Powderly, W. G., Granich, G. G., Herzid, G. P., and Krogstad, D. J. (1987). HPLC measurement of amphotericin B serum levels in cancer patients. 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract 782)
310. Powderly W.G., Kobayashi G.S., Herzig G.P., and Medoff G. Amphotericin B- resistant yeast infection in severely immunocompromised patients. Am. J. Med. 84 (1988) 826-832
311. Prevost E., and Bannister E. Detection of yeast septicemia by biphasic and radiometric methods. J. Clin. Microbiol. 12 (1981) 655-660
312. Price M.F., LaRocco M.T., and Gentry L.O. Fluconazole susceptibilities of Candidu species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob. Agents Chemother. 38 (1994) 1422-1424
313. Proffitt R.T., Storius S.M., Chiang L., Sullivan I., and Adler-Moore J.P. Pharmacology and toxicology of a liposornal formulation of amphotericn B (AmBisome) in rodents. J. Antimicrob. Chemother. 28 (1991) 49-61
314. Pursley T.J., Blornquist I.K., Abraham J., Andersen H.F., and Bartley J.A. Fluconazole-induced congenital anomalies in three infants. Clin. Infect. Dis. 22 (1996) 336-340
315. Raad I.I., and Bodey G.P. Infectious complications of indwelling vascular catheters. Clin. Infect. Dis. 15 (1992) 197-210
316. Reagan D.R., Pfaller M.A., Hollis R.J., and Wenzel R.P. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J. Clin. Microbiol. 28 (1990) 2733-2738
317. Reiss E., Stockman L., Kuydendall T.J., and Smith S.J. Dissociation of mannan-serum complexes and detection of Candida albicans mannan by enzyme immunoassay variations. Clin. Chem. 28 (1982) 306-310
318. Reiss E., and Morrison C.J. Nonculture methods for diagnosis of disseminated candidiasis. Clin. Microbiol. Rev. 6 (1993) 311-323
319. Reller L.B. Recent and innovative methods for detection of bacteremia and fungemia. Am. J. Med. 75 Suppl. IB (1983) 26-30
320. Restrepo A., Robledo J., Gomez I., Tabares A.M., and Gutierrez R. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch. Dermatol. 122 (1986) 413-417
321. Rex J.H. Itraconazole-digoxin inceraction. Ann. Intern. Med. 116 (1992) 526
322. Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., Van der Horst C.M., Edwards J.E., Washburn R.G., Scheld W.M., Karchmer A.W., Dine A.P., Levenstein M.J., Webb C.D., the Candidemia Study Group, and and the NIAID Mycoses Study Group. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331 (1994) 1325-1330
323. Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., Serody J., Edwards J., and Washburn R.G. Intravascular catheter exchanges and the duration of candidemia. Clin. Infect. Dis. 21 (1995) 994-996 the NIAID Mycoses Study Group
324. Rex J.H., Pfaller M.A., Barry A.L., Nelson P.W., Webb C.D., the NIAID Mycoses Study Group, and and the Candidemia Study Group. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole vs. amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob. Agents Chemother. 39 (1999) 40-44
325. Rex J.H., Rinaldi M.G., and Pfaller M.A. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39 (1995) 1-8
326. Riley D.K., Pavia A.T., Beatty P.G., Petersen F.B., Spruance J.L., Stokes R., and Evans T.G. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am. J. Med. 97 (1994) 509-514
327. Roberts G.D., Horstmeier C., Hall M., and Washington J.A.J. Recovery of yeast from vented blood culture bottles. J. Clin. Microbiol. 2 (1975) 261-265
328. Rohner P., Pepey B., and Auckenthaler R. Comparison of BacT/Alert with Signal blood culture system. J. Clin. Microbiol. 33 (1995) 313-317
329. Rotrosen D., Edwards J.E.J., Gibson T.R., Moore J.C., Cohen A.H., and Green I. Adherence of Candida to cultured vascular endothelial cells: Mechanisms of attachment and endothelial cell penetration. J. Infect. Dis. 152 (1985) 1264-1274
330. Rubin P.C., Wilton L.V., and Inman W.H.W. Fluconazole and pregnancy: Results of a prescription event-monitoring study. Int. J. Gynuecol. Obstet. 37 (1992) 25-27
331. Sabra R., and Branch R.A. Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats. Antimicrob. Agents Chemother. 35 (1991) 2509-2514
332. Sachs M.K., Blanchard L.M., and Green P.J. Interaction of itraconazole and digoxin. Clin. Infect. Dis. 16 (1993) 400-403
333. Safe L.M., Safe S.H., Subden R.E., and Morris D.C. Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis. Can. I. Microbiol. 23 (1977) 398-401
334. Sahai J., Gallicano K., Pakuts A., and Cameron D.W. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J. Infect. Dis. 169 (1994) 1103-1107
335. Sarnaranayake Y.H., and Samaranayake L.P. Candida krusei: Biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. J. Med. Microbiol. 41 (1994) 295-310
336. Sampol E.B., LaCarelle B., Rajaonarisom J.F., Catalin J., and Durand A. Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. J. Clin. Pharmacol. 40 (1995) 83-86
337. Sanchez M.L., Pfaller M.A., Cabezuedo I., Bale M., and Buschelman B. Diagnosis of disseminated candidiasis in hospitalized patients using the CAND-TEC agglutination assay. Mycopathologia 118 (1992) 153-162
338. Sandhu F.S., Kline B.C., Stockman L., and Roberts G.D. Molecular probes for diagnosis of fungal infections. J. Clin. Microbiol. 33 (1995) 2913-2919
339. Sawyer R.T., Moon R.J., and Beneke E.S. Hepatic clearance of Candida albicans in rats. Infect. Immun. 14 (1976) 1348-1455
340. Saxen H., Hoppu K., and Pojhavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin. Pharmacol. Ther. 54 (1993) 269-277
341. Schaffner A., and Böhler A. Amphotericin B refractory aspergillosis after itraconazole: Evidence for significant antagonism. Mycoses 36 (1993) 421-424
342. Schaffner A., and Frick P.G. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J. Infect. Dis. 151 (1985) 902-910
343. Scheven M., and Scheven M.-L. Interaction between azoles and amphotericin B in the treatment of candidiasis. Clin. Infect. Dis. 20 (1995) 1079
344. Scheven M., and Schwegler F. Antagonistic interactions between azoles and amphoteri- cin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob. Agents Chemother. 39 (1995) 1779-1783
345. Scheven M., Scheven C., Hahn K., and Senf A. Post-antibiotic effect and post-exposure polyene antagonism of azole antimycotics in Candida albrcans: Dependency on lipophiiia. Mycoses 38 Suppl. 1 (1995) 14-21
346. Scholer H.J. Flucytosine. In: Speller D.C.E. (Ed). "Antifungal Chemotherapy" (1977), John Wiley & Sons, Chichester 35-106
347. Schonebeck J., Polak A., Fernex M., and Scholer H.J. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy 18 (1973) 321-336
348. Schroter G.P.J., Hoeslscher M., and Putnam C.W. Fungus infections after liver transplantation. Ann. Surg. 186 (1977) 115-122
349. Seabury J.H., and Dascomb H.E. Experience with amphotericin B for the treatment of systemic mycoses. Arch. Intern. Med. 102 (1958) 960-976
350. Seay R.E., Larson T.A., Toscano J.P., Bostrom B.C., O'Leary M.A., and Uden D.L. Pharmacokinetics of fluconazole in immunocompromised children with leukemia or other hematologic diseases. Pharmucotherapy 15 (1995) 52-58
351. Sharkey P.K., Rinaldi M.G., Dunn J.F., Hardin T.C., Fetchick R.J., and Graybill J.R. High-dose itraconazole in the treatment of severe mycoses. Antimicrob. Agents Chemother. 35 (1991) 707-713
352. Sherertz R.J., Raad I.I., Belani A., Koo L.C., Rand K.H., Pickett D.L., Straub S.A., and Fauerbach L.L. Three-year experience with sonicated vascular catheter cultures in a clinical microbiology laboratory. J. Clin. Microbiol. 28 (1990) 76-82
353. Slavin M.A., Osborne B., Adams R., Levenstein M.J., Schoch H.G., Feldman A.R., Meyers J.D., and Bowden R.A. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation-A prospective, randomized, double-blind study. J. Infect. Dis. 171 (1995) 1545-1548
354. Smith S.R., Galloway M.J., Reilly J.T., and Davies J.M. Amiloride prevents amphotericin B-related hypokalemia in neutropenia patients. J. Clin. Pathol. 41 (1988) 494-497
355. Sokol-Anderson M.L., Brajtburg J., and Medoff G. AmphotericinB-induced oxidative damage and killing of Candida albicuns. J. Infect. Dis. 154 (1986) 76-83
356. Sokol-Anderson M.L., Sligh J.E., Elberg S., Brajtburg J., Kobayashi G.S., and Medoff G. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob. Agents Chemother. 37 (1988) 702-705
357. Solomkin J.S. Pathogenesis and management of Candida infection syndromes in nonneutropenic patients. New Horizons 1 (1993) 202-213
358. Solomkin J.S., and Simmons R.L. Candida infection in surgical patients. World J. Surg. 4 (1980) 381-394
359. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N. Engl. J. Med. 317 (1987) 812-818
360. Spitzer T.R., Creger R.J., Fox T.M., et al. Rapid infusion of amphotericin B: Effective and well-tolerated therapy for neutropenic fever. Pharmutherupeutica 5 (1989) 305-311
361. Stallybrass F.C. Candida precipitins. J. Pathol. 87 (1964) 89-97
362. Stamm A.M., Diasio R.B., Dismukes W.E., Shadomy S., Cloud G.A., Bowles C.A., Karam G.H., and Espinel-lngroff A. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am. J. Med. 83 (1987) 236-242
363. Stone H.H., Kilb L.D., Currie C.A., Ghever C.E., and Cuzzell J.Z. Candida sepsis: Pathogenesis and principles of treatment. Ann. Surg. 179 (1974) 697-711
364. Strinden W.D., Helgerson R.B., and Maki D.G. Candida septic thrombosis of the great central veins associated with central catheters. Ann. Surg. 202 (1985) 653-658
365. Sud I.J., Chou D.L., and Feingold D.S. Effect of free fatty acids on liposome susceptibility ot imidazole antifungals. Antimicrob. Agents Chemother. 16 (1979) 660-663
366. Sugar A.M., Saunders C., and Diamond R.D. Successful treatment of Candidu osteomyelitis with fluconazole. A noncomparative study of two patients. Diagn. Microbiol. Infect. Dis. 13 (1990) 517-520
367. Sugar A.M., Htchcock C.A., Troke P.F., and Picard M. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob. Agents Chemother. 39 (1995) 598-601
368. Sugar A.S. Use of amphotericin B with azole antifungal drugs: What are we doing. Antimicrob. Agents Chemother. 39 (1995) 1907-1912
369. Takacs F.J., Tomkiewicz Z.M., and Merrril J.P. Amphotericin B nephrotoxicity with irreversible renal failure. Ann. Intern. Med. 59 (1963) 716-724
370. Tang C. Successful treatment of Candidu albicans osteornyelitis with fluconazole. J. Infect. 26 (1993) 89-92
371. Taschdjian C.L., Burchall J.J., and Kozinn P.J. Rapid identification of Candidu albicans by filamentation on serum and serum substitutes. Am. J. Dis. Child 99 (1960) 212-215
372. Telenti A., Steckelberg J.M., Stockman L., Edson R.S., and Roberts G.D. Quantitative blood cultures in candidemia. Muyo Clin. Proc. 66 (1991) 1120-1123
373. Terrel C.L., and Herrnans P.E. Antifungal agents used for deep-seated mycotic infections. Muyo Clin. Proc. 62 (1987) 116-128
374. Todeschini G., Murari C., Bonesi R., Pizzolo G., Arnaddi G., Ambrosetti A., Ceru S., Piacentini I., Martini N., Montresor P., and Perona G. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies. Eur. J. Clin. Microbiol. Infect. Dis. 12 (1993) 614-618
375. Tricot G., Joosten E., Boogaerts M.A., Vande Pitte J., and Cauwenbergh G. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocy-topenia: Preliminary results of two nonrandomized studies. Rev. Infect. Dis. 9 Suppl. l (1987) s94-s99
376. Tucker R.M., Denning D.W., Hanson L.H., Rinaldi M.G., Graybill J.R., Sharkey P.K., Pappagianis D., and Stevens D.A. Interaction of azoles with rifampin, phenytoin, and carbamazepine: In vitro and clinical observations. Clin. Infect. Dis. 14 (1992) 165-174
377. Tynes B.S., Utz J.P., Bennett J.E., and Alling D.W. Reducing amphotericin B reactions. A double-blind study. Am. Rev. Respir. Dis. 87 (1963) 264-268
378. Utz J.P., Garriques I.L., Sande M.A., Warner J.R., Mandell G.L., McGehee R.F., and Duma R.J. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J. Infect. Dis. 132 (1975) 368-373
379. Uzum O., and Anaissie E.J. Antifungal prophylaxis in patients with hematologic malignancies: A reappraisal. Blood 86 (1995) 2063-2072
380. Van Cauteren H., Lampo J., Vandenberghe J., Vanparys P., Coussemen R., Coster D., and Marsboom R. Toxicological profile and safety evaluation of antifungal azole derivatives. Mycoses 32 (1989) 60-66
381. Van den Bossche H., Willemsens G., Cools W., Marichal P., and Lauwers W. Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. Biochem. Soc. Trans 11 (1983) 665-667
382. van der Merr J.W.M., Keuning J.J., Scheijgrond H.W., Heykants J., van Cutsem J., and Brugmans J. The influence of gastric acidity on the bioavailability of ketoconazole. J. Antimicrob. Chemother. 6 (1980) 552-554
383. van Deventer A.J.M., van Vliet H.J.A., Voogd L., Hop W.C.J., and Goessens W.H.F. Increased specificity of antibody detection in surgical patients with invasive candidiasis with cytoplasmic antigens depleted of mannan residues. J. Clin. Microbiol. 31 (1993) 994-997
384. van Deventer A.J.M., van Vlient H.I.A., Hop W.C.J., and Goessens W.H.F. Diagnostic value of anti-Candida enolase antibodies. J. Clin. Microbiol. 32 (1994) 17-23
385. van Deventer A.J.M., Goessens W.H.F., van Belkum A., van Vliet H.J.A., van Etten E.W.M., and Verbrugh H.A. Improved detection of Candida ulbicuns by PCR in blood of neutropenic mice with systemic candidiasis. J. Clin. Microbiol. 33 (1995) 625-628
386. van Deventer A.J.M., Goessens W.H.F., van Belkum A., van Etten E.W.M., van Vliet H.J.A., and Verbrugh H.A. PCR monitoring of response to liposomal amphotericin B treatment of systemic candidiasis in neutropenic mice. J. Clin. Microbiol. 34 (1996) 25-28
387. Van Etten E.W.M., Ten Kate M.T., Stearne L.E.T., and Bakker-Woudenberg A.J.M. Amphotericin B liposomes with prolonged circulation in blood: In vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob. Agents Chemother. 39 (1995) 1954-1958
388. Van Peer A., Woestenborghs R., Heykants J., Gasparini R., and Gauwenbergh G. The effects of food and dose on the oral systemic availability of itraconzole in healthy subjects. Eur. J. Clin. Pharmacol. 36 (1989) 423-426
389. Varhe A., Olkkola K.T., and Neuvonen P.J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 56 (1994) 601-607
390. Vendicti M., de Bernardis F., Micozzi A., Pontieri E., Chirletti P., Cassone A., and Martino P. Fluconazole treatment of catheter-related right-sided endocarditis caused by Candida albicans and associated with endophthalmitis and folliculitis. Clin. Infect. Dis. 14 (1992) 422-426
391. Viviani M.A., Tortorano A.M., Woenstenborghs R., and Cauwenbergh G. Experience with itraconazole in deep mycosis in Northen Italy. Mykosen 30 (1987) 233-244
392. Voss A., Hollis R.J., Pfaller M.A., Wenzel R.P., and Doebbeling B.N. Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J. Clin. Microbiol. 32 (1994) 975-980
393. Walsh T.J., Hathorn J.W., Sobel J.D., Merz W.G., Sanchez V., Maret S.M., Buckley H.R., Pfaller M.A., Schaufele R., Sliva C., Navarro E., Lecciones J., Chandrasekar P., and Lee J. Detection of circulating Candida enolase by immunoassay in patients with cancer and invasive candidiasis. N. Engl. J. Med. 324 (1991) 1026-1031
394. Walsh, T. J., Hiemenz, J. W., Seibel, N., and Anaissie, E. J. (1994a). Amphotericin B lipid complex in the treatment of 225 cases of invasive mycoses. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract M69)
395. Walsh T.J., Lee J.W., Sen T., Schaufele R., Bacher J., Switchenko A.C., Goodman T.C., and Pizzo P.A. Serum D-arabinitol measured by automated quantitative enzymatic assay for detection and therapeutic monitoring of experimental disseminated candidiasis: Correlation with tissue concentrations of Candida albicans. J. Med. Vet. Mycol. 32 (1994) 205-215
396. Walsh T.J., Francesconi A., Kasai M., and Chanock S.J. PCR and single-strand conformational polymorphism for recognition of medically important opportunistic fungi. J. Clin. Microbiol. 33 (1995) 3216-3220
397. Walsh T.J., Merz W.G., Lee J.W., Schaufele R., Sein T., Whitcomb P.O., Ruddel M., Burns W., Wingard J.R., Swichenko A.C., Goodman T., and Pizzo P.A. Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzymatic detection of serum D-arabinitol. Am. J. Med. 99 (1995) 164-172
398. Warnock D., Turner A., and Burker J. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. J. Antimicrob. Chemother. 21 (1988) 93-100
399. Warren R., Richardson M.D., and White L.O. Enzyme-linked immunosorbent assay of antigens from Candida albicans circulating in infected mice and rabbits: The role of mannan. Mycoputhologzu 66 (1979) 179-182
400. Weems Jr. J.J. Candida purupsilosis: Epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin. Infect. Dis. 14 (1992) 756-766
401. Weiner M.H., and Coats-Stephen M. Immunodiagnosis of systemic candidiasis: Mannan antigenemia detected by radioimrnunoassay in experimental and human infections. Ann. Intern. Med. 99 (1979) 777-782
402. Wells C., and Lever A.M. Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge. J. Infect. 24 (1991) 111-112
403. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., and Wenzel R.P. Hospital acquired candidemia: The attributable mortality and excess length of stay. Arch. Intern. Med. 148 (1988) 2642-2645
404. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., and Wenzel R.P. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch. Intern. Med. 149 (1989) 2349-2353
405. Whimbey E., Wong B., Kiehn T.E., and Armstrong D. Clinical correlations of serial quantitative blood cultures determined by lysis-centrifugation in patients with persistent septicemia. J. Clin. Microbiol. 19 (1984) 766-771
406. Wilson M.L., Davis T.E., Mirrett S., Reynolds J., Fuller D., Allen S.D., Flint K.K., Koontz F., and Reller L.B. Controlled comparison of the BACTEC high-blood-volume fungal medium, BACTEC plus 26 aerobic blood culture bottle, and 10-milliliter isolator blood culture system for detection of fungemia and bacteremia. J. Clin. Microbiol. 31 (1993) 865-871
407. Wingard J.R., Merz W.C., and Saral R. Candida tropicalis: A major pathogen in immunocompromised patients. Ann. Intern. Med. 91 (1979) 539-543
408. Wingard J.R., Merz W.G., Rinaldi M.G., Johnson T.R., Karp J.E., and Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325 (1991) 1274-1277
409. Wingard J.R., Merz W.G., Rinaldi M.G., Miller C.B., Karp J.E., and Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37 (1993) 1847-1849
410. Winn W.A. Coccidioidomycosis and amphotericin B. Med. Clin. North Am. 47 (1963) 1131-1148
411. Winston D.J., Chandrasekar P.H., Lazarus H.M., Goodman J.L., Silber J.L., Horowitz K., Shadduck R.K., Rosenfeld C.S., Ho W.G., Islam M.Z., et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 118 (1993) 495-503
412. Wishart J.M. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. J. Am. Acad. Dermatol. 17 (1987) 220-223
413. Wong B., Bernard J.W., Gold M., Fong D., and Armstrong D. The arabinitol appearance rate in laboratory animals and humans: Estimation from the arabinitokreati-nine ratio and relevance to the diagnosis of candidiasis. J. Infect. Dis. 146 (1982) 353-359
414. Woods R.A., Bard M., Jackson I.E., and Drutz D.J. Resistance to polyene antibiotics and correlated sterol changes in two isolate of Candida tropicalis from a patient with an amphotericin B-resistant funguria. J. Infect. Dis. 129 (1974) 53-58
415. Yeh J., Soo S.C., Summerton C., and Richardson C. Potentiation of action of warfarin by itraconazole. Br. Med. J. 301 (1990) 669
416. Young R.C., Bennett J.E., Geelhoed G.W., and Levine A.S. Fungemia with compromised host resistance: A study of 70 cases. Ann. Intern. Med. 80 (1974) 605-612